Praxis Precision Medicines (PRAX) Misses Q3 EPS by 76c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts PRAX Hot Sheet
Join SI Premium – FREE
Praxis Precision Medicines (NASDAQ: PRAX) reported Q3 EPS of ($2.75), $0.76 worse than the analyst estimate of ($1.99). Revenue for the quarter came in at $302 thousand versus the consensus estimate of $328.56 thousand.
For earnings history and earnings-related data on Praxis Precision Medicines (PRAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Howard Hughes Holdings to join S&P SmallCap 600 on Oct. 28
- Goldman Sachs sees US stocks dip on tech earnings and macro shifts
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
